-
公开(公告)号：US20140343011A1
公开(公告)日：2014-11-20
申请号：US14006771
申请日：2012-03-23
IPC分类号： A61K31/728 , A23L2/38 , A23L2/52 , A61K45/06
CPC分类号： A61K31/737 , A23L2/38 , A23L2/52 , A23V2002/00 , A61K9/0034 , A61K31/728 , A61K45/06 , C08B37/0072 , A61K2300/00
摘要： Described herein are methods for treating or preventing urological inflammation in a subject comprising administering to the subject an effective amount of a compound comprising a. a modified hyaluronan or a pharmaceutically acceptable salt or ester thereof, wherein said hyaluronan or its pharmaceutically acceptable salt or ester comprises at least one sulfate group and at least one primary C-6 hydroxyl position of an N-acetyl-glucosamine residue comprising an alkyl group or fluoroalkyl group; b. a partially or fully sulfated hyaluronan or the pharmaceutically acceptable salt or ester thereof, or a combination thereof.
摘要翻译： 本文描述了治疗或预防受试者泌尿系炎症的方法，包括向受试者施用有效量的包含a。 修饰的透明质酸或其药学上可接受的盐或酯，其中所述透明质酸或其药学上可接受的盐或酯包含至少一个硫酸根基团和包含烷基的N-乙酰基 - 葡糖胺残基的至少一个C 6羟基位置 或氟烷基; b。 部分或完全硫酸化的透明质酸或其药学上可接受的盐或酯，或其组合。
-
公开(公告)号：US09522162B2
公开(公告)日：2016-12-20
申请号：US14006771
申请日：2012-03-23
IPC分类号： A61K31/728 , A61K31/737 , C08B37/08 , A61K45/06 , A23L2/38 , A23L2/52 , A61K9/00
CPC分类号： A61K31/737 , A23L2/38 , A23L2/52 , A23V2002/00 , A61K9/0034 , A61K31/728 , A61K45/06 , C08B37/0072 , A61K2300/00
摘要： Described herein are methods for treating or preventing urological inflammation in a subject comprising administering to the subject an effective amount of a compound comprising a. a modified hyaluronan or a pharmaceutically acceptable salt or ester thereof, wherein said hyaluronan or its pharmaceutically acceptable salt or ester comprises at least one sulfate group and at least one primary C-6 hydroxyl position of an N-acetyl-glucosamine residue comprising an alkyl group or fluoroalkyl group; b. a partially or fully sulfated hyaluronan or the pharmaceutically acceptable salt or ester thereof, or a combination thereof.
摘要翻译： 本文描述了治疗或预防受试者泌尿系炎症的方法，包括向受试者施用有效量的包含a。 修饰的透明质酸或其药学上可接受的盐或酯，其中所述透明质酸或其药学上可接受的盐或酯包含至少一个硫酸根基团和包含烷基的N-乙酰基 - 葡糖胺残基的至少一个C 6羟基位置 或氟烷基; b。 部分或完全硫酸化的透明质酸或其药学上可接受的盐或酯，或其组合。
-
公开(公告)号：US08343942B2
公开(公告)日：2013-01-01
申请号：US13069860
申请日：2011-03-23
IPC分类号： A61K31/728 , A61K9/00 , C08B37/08 , A61P27/02 , A61P27/04
CPC分类号： A61K31/737 , A61K45/06 , A61K2300/00
摘要： Described herein are methods for treating interstitial cystitis in a subject comprising administering to the subject an effective amount of a compound which is a modified hyaluronan or a pharmaceutically acceptable salt or ester thereof, wherein said hyaluronan or its pharmaceutically acceptable salt or ester comprises at least one sulfate group and the primary C-6 hydroxyl proton of at least one N-acetyl-glucosamine residue is substituted with an unsubstituted alkyl group or fluoroalkyl group.
摘要翻译： 本文描述了用于治疗受试者间质性膀胱炎的方法，包括向受试者施用有效量的作为修饰的透明质酸或其药学上可接受的盐或酯的化合物，其中所述透明质酸或其药学上可接受的盐或酯包含至少一种 硫酸基和至少一个N-乙酰基 - 葡糖胺残基的C 1 -C 6羟基质子被未取代的烷基或氟代烷基取代。
-
公开(公告)号：US20120021968A1
公开(公告)日：2012-01-26
申请号：US13069860
申请日：2011-03-23
IPC分类号： A61K38/02 , A61K31/7088 , G01N33/573 , A61P29/00 , A61P13/08 , A61P13/10 , A61P15/02 , A61P15/00 , A61P13/00 , A61K31/728 , A61P13/12
CPC分类号： A61K31/737 , A61K45/06 , A61K2300/00
摘要： Described herein are methods for treating or preventing urological inflammation in a subject comprising administering to the subject an effective amount of a compound comprising a. a modified hyaluronan or a pharmaceutically acceptable salt or ester thereof, wherein said hyaluronan or its pharmaceutically acceptable salt or ester comprises at least one sulfate group and at least one primary C-6 hydroxyl position of an N-acetyl-glucosamine residue comprising an alkyl group or fluoroalkyl group; b. a partially or fully sulfated hyaluronan or the pharmaceutically acceptable salt or ester thereof, or a combination thereof.
摘要翻译： 本文描述了治疗或预防受试者泌尿系炎症的方法，包括向受试者施用有效量的包含a。 修饰的透明质酸或其药学上可接受的盐或酯，其中所述透明质酸或其药学上可接受的盐或酯包含至少一个硫酸根基团和包含烷基的N-乙酰基 - 葡糖胺残基的至少一个C 6羟基位置 或氟烷基; b。 部分或完全硫酸化的透明质酸或其药学上可接受的盐或酯，或其组合。
-
-
-
搜索结果
4 条记录 (耗时 0.026 秒)
